#### 1 Recapitulation of Cellular Senescence, Inflammation, and Fibrosis in Human Kidney-

#### 2 Derived Tubuloids by Repeated Cisplatin Treatment

- 3 Yuki Nakao<sup>1#</sup>, Yutaro Mori<sup>1#\*</sup>, Makiko Mori<sup>1</sup>, Shintaro Mandai<sup>1</sup>, Tamami Fujiki<sup>1</sup>, Hiroaki
- 4 Kikuchi<sup>1</sup>, Fumiaki Ando<sup>1</sup>, Koichiro Susa<sup>1</sup>, Takayasu Mori<sup>1</sup>, Yuma Waseda<sup>2</sup>, Soichiro Yoshida<sup>2</sup>,
- 5 Yasuhisa Fujii<sup>2</sup>, Eisei Sohara<sup>1</sup>, Shinichi Uchida<sup>1</sup>
- <sup>6</sup> <sup>1</sup>Department of Nephrology and <sup>2</sup>Department of Urology, Graduate School of Medical and Dental
- 7 Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.
- 8 <sup>#</sup>These authors contributed equally to this work.
- 9
- 10 Lead contact and Corresponding author:
- 11 Yutaro Mori, MD, PhD
- 12 Department of Nephrology
- 13 Graduate School of Medical and Dental Sciences
- 14 Tokyo Medical and Dental University
- 15 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
- 16 Phone: +81-3-5803-5214; Fax: +81-3-5803-5215; Email: <u>y-mori.kid@tmd.ac.jp</u>

- 18 Runing title:
- 19 Recapitulation of Cellular Senescence in Human Tubuloids
- 20

#### 21 Abstract

22 In the pursuit of more accurate pathophysiological models for assessing renal drug response, the development of kidney organoids derived from human pluripotent stem cells represents a 23 24 significant step forward. However, recapitulating aging/senescence-associated pathophysiology 25 within these models remains challenging. Here, we present an innovative approach to generate 26 more homogeneous epithelial-like structures known as "tubuloid" using primary human renal 27 proximal tubular epithelial cells (hRPTECs) cultured from human resected kidneys, as a refined 28 alternative. We evaluated the efficacy of tubuloids using cisplatin treatment at three different 29 concentrations: 0.2, 2.0, and 20.0 µg/mL. Tubuloids showed highly differentiated structures with 30 proximal tubular epithelial cells that expressed lotus tetragonolobus lectin and LRP2/Megalin. 31 Upon exposure to cisplatin,  $\gamma$ H2AX expression increased in a dose-dependent manner, indicating 32 DNA damage. Cisplatin treatment also resulted in the expression of Kidney Injury Molecule-1 33 (KIM-1) and Cleaved Caspase-3, which are indicators of kidney injury and apoptotic signaling, 34 respectively. Repeated cisplatin administration resulted in upregulation of the cellular senescence 35 marker p16, alongside increased secretion of inflammatory cytokines IL-1β and IL-6, indicating 36 the induction of a senescence-associated secretory phenotype (SASP). Furthermore, supernatant 37 collected from cisplatin-treated tubuloids induced myofibroblast activation, indicating the onset of 38 renal fibrosis. We successfully established a tubuloid-based model of cisplatin-induced kidney 39 injury using hRPTECs. Tubuloids provide a novel platform for studying the response of renal 40 epithelial cells to toxins and therapeutics. Tubuloids can replicate cellular senescence, SASP, and 41 fibrosis, making them a promising pathophysiological model for chronic kidney disease (CKD), 42 providing insights into the disease's fibrotic mechanisms.

#### 44 Keywords

45 organoid, tubuloid, cisplatin nephrotoxicity, fibrosis, chronic kidney disease

46

#### 47 Translational Statement

- 48 Recapitulating aging/senescence-associated pathophysiological reaction in kidney organoids
- 49 remains challenging. Our study reveals that tubuloids could be novel candidate for chronic
- 50 kidney disease (CKD) model.

#### 51 Introduction

52 Chronic kidney disease (CKD) is an irreversible, progressive condition characterized by the 53 gradual sclerosis of glomeruli, accompanied by tubular atrophy, interstitial fibrosis, and infiltration 54 of inflammatory cells [1]. Despite its significant impact on global health, the underlying 55 pathogenic mechanisms of CKD are poorly understood, and a definitive cure has yet to be 56 discovered.

57 In recent years, a shared mechanism for inflammation and fibrosis in CKD has emerged. It 58 is proposed that the initial trigger is DNA damage in tubular epithelial cells, which initiates a 59 cascade involving DNA damage response, cell cycle arrest [2], cellular senescence [3, 4], and the 60 subsequent development of the senescence-associated secretory phenotype (SASP) [5]. To 61 investigate these processes, various models have been created, including cell and animal models, 62 as well as kidney organoids derived from human induced pluripotent stem cells (iPSCs) [6] or 63 human embryonic stem cells (ESCs). These models show promise in understanding the 64 pathogenesis of CKD and investigating potential therapeutic interventions [7]. Nonetheless, one 65 critical limitation of existing models is their inability to fully capture the aging process, particularly 66 the phenomenon of cellular senescence, which manifests prominently in humans with a lifespan 67 greater than 80 years. Experimental animals such as mice, with a lifespan of only two years, do 68 not fully replicate the range of age-related diseases associated with cellular senescence found in 69 humans.

Furthermore, despite progress, kidney organoids derived from iPSCs or ESCs have primarily focused on replicating fetal kidney development stages, falling far short of accurately mimicking age-related diseases such as CKD.

73 In this context, "tubuloids," a three-dimensional structure resembling renal tubules, were 74 first reported in 2019. These tubuloids come from adult primary human renal proximal tubular 75 epithelial cells (hRPTECs) [8]. Schutgens et al. pioneered the culture of primary hRPTECs derived 76 from adult human kidneys and urine, successfully producing tubuloids capable of replicating viral 77 infections in proximal tubules and hereditary diseases [9]. Building on this work, we have further 78 refined the tubuloid generation protocol with human resected kidneys [10]. Our research has 79 focused on understanding the response of tubuloids to a nephrotoxicant and a potential therapeutic 80 agent. Despite these advances, developing a comprehensive pathophysiological model for aging 81 or senescence-associated diseases using tubuloids remains a promising area of research.

82 Cisplatin, a commonly used therapeutic agent for various malignancies, including lung 83 cancer, has a well-known side effect known as cisplatin-induced nephropathy [11, 12]. This 84 condition is defined by the induction of DNA damage in the renal proximal tubules [13]. The 85 cellular response to this damage includes cell cycle arrest during the repair phase following 86 cisplatin-induced injury, which eventually leads to cellular senescence and SASP. These processes 87 are thought to be the final detrimental mechanisms that underpin the progression from acute kidney 88 injury (AKI) to CKD [14, 15]. Thus, modeling cisplatin-induced nephropathy is not only useful 89 for studying nephrotoxicity but also has the potential to mimic the progression of CKD.

The primary goal of this study was to assess the disease-modeling potential of tubuloids by exposing them to cisplatin to reproduce cisplatin-induced nephropathy. Furthermore, we wanted to investigate whether tubuloids could replicate cellular senescence and its associated responses beyond the immediate effects of cisplatin nephrotoxicity to simulate the transition from AKI to CKD, or even model CKD itself.

#### 96 Methods

97 Cell culture experiment: Human kidney samples were collected from patients undergoing 98 clinically indicated nephrectomy at the Tokyo Medical and Dental University Hospital in Tokyo, 99 Japan. The protocol was approved by the Institutional Review Board of the Ethics Committee of 100 Tokyo Medical and Dental University (M2022-005). Human renal proximal tubular epithelial cells 101 (hRPTECs) were isolated from unaffected areas of kidneys removed during nephrectomy 102 procedures performed on patients with renal cell carcinoma or urinary tract malignancies by 103 modifying a previously established protocol[37]. Briefly, the isolation procedure involved mincing 104 the human renal cortex and then digesting it in a solution of Collagenase type II (1.0 mg/mL) (Worthington Biochemical, NJ, USA). The enzyme reaction was terminated with fetal bovine 105 106 serum (FBS), and the samples were resuspended in hRPTECs culture medium containing 107 DMEM/F-12 (Nacalai Tesque, Kyoto, Japan), with BSA (Nacalai Tesque), Antibiotic-108 Antimycotic (ThermoFisher Scientific, MA, USA), hydrocortisone (ThermoFisher Scientific, MA, 109 USA), ITS liquid media supplement (Sigma-Aldrich, MO, USA), and human recombinant 110 epidermal growth factor (EGF) (ThermoFisher Scientific, MA, USA). The epithelial cells were 111 cultured for 7-10 days before being used in experiments.

To make mouse primary kidney fibroblasts (MPKFs), a 12-week old male C57BL/6J mouse was sacrificed. MPKFs were isolated by mincing the mouse kidneys and digesting them in a solution of Collagenase type II (1.0 mg/mL). The enzyme reaction was stopped with FBS, and the samples were resuspended in DMEM with 10% FBS, 5 ng/ml FGF-basic (ThermoFisher Scientific), and Antibiotic-Antimycotic. The MPKFs were used after 3 to 5 passages. All cells were maintained in a CO<sub>2</sub> incubator (5% CO<sub>2</sub>) at 37°C to ensure optimal growth conditions. All animal studies were performed in accordance with the guidelines for animal research of Tokyo

Medical and Dental University. The study protocol was approved by the Animal Care and Use
Committee of Tokyo Medical and Dental University (approval no. A2023-109C).

121

Human Renal Tubuloids Culture: hRPTECs were seeded onto ultralow attachment plates at a density of  $5.0 \times 10^5$  cells/well using Advanced RPMI 1640 medium (ThermoFisher Scientific), supplemented with 5% FBS. After a 2-day incubation period, Matrigel (Corning, NY, USA) was added to stimulate tubuloid formation. The following day, the culture medium was changed to Advanced RPMI 1640 medium with 5% FBS, EGF, FGF2, and HGF (tubuloids media). Media was changed once or twice weekly to maintain optimal cell growth conditions. Tubuloids were usually ready for experimentation within 1–2 weeks of starting the culture.

129

Fibrosis bioassay. The tubuloids were treated with or without cisplatin on a repeated basis.
Following a 48-hour exposure period, the media was replaced with serum-free DMEM to facilitate
conditioning. After an additional 48 hours of incubation, the culture supernatants were collected
as conditioned media.

134 MPKFs were uniformly plated at a density of  $2.0 \times 10^4$  cells/well in an 8-well chamber 135 slide (Nunc Lab-Tek Chamber Slide system) (ThermoFisher Scientific) with 10% FBS-DMEM. 136 The next day, the conditioned media harvested from the tubuloids was added to MPKFs and 137 incubated for 48 hours. The MPKFs on the 8-well chamber slide were then washed twice with PBS 138 and immunostained as described below.

139

140 Immunofluorescence staining. The tubuloids were fixed with 4% paraformaldehyde (PFA) in
141 PBS and permeabilized with 0.1% Triton X-100 in PBS. The tubuloids were then blocked with

142 3% BSA in PBS and incubated with primary antibodies for 1 hour. Tubuloids were washed 143 thoroughly with PBS and then incubated with secondary antibodies for 30 minutes. After another 144 round of PBS washing, the tubuloids were placed on glass slides. The slides were mounted with 145 Prolong Glass Antifade Mountant with NucBlue Stain (ThermoFisher Scientific) and cover-146 slipped for fluorescence microscopy.

147 The following primary antibodies were used: rabbit anti-LRP2 / Megalin antibody (1:100) 148 (ab236244, Abcam, MA, USA), rabbit anti-γH2AX antibody (1:200) (#9718, Cell Signaling 149 Technology, MA, USA), mouse anti-Na<sup>+</sup>/K<sup>+</sup>-ATPase antibody (1:200) (05-369, Sigma-Aldrich), 150 mouse anti-KIM-1 antibody (1:200) (AF1750, R&D systems, MN, USA), rabbit anti-caspase-3 151 antibody (1:200) (#9664, Cell Signaling Technology), rabbit anti-Vimentin antibody (1:200) 152 (10366-1-AP, Proteintech, IL, USA), rabbit anti-p16-INK4A polyclonal antibody (1:200) (10883-153 1-AP, Proteintech), rabbit anti-IL-1 $\beta$  polyclonal antibody (1:200) (bs-0812R, Bioss, MA, USA) 154 and rabbit anti- $\alpha$ SMA antibody conjugated with Cy3 (1:400) (C6198, Sigma-Aldrich) were used. 155 To stain the brush border of the proximal tubular epithelium, LTL, Biotinylated (B-1325-2, Vector 156 Laboratories, CA, USA) was used instead of primary antibodies (1:200). Streptavidin, Alexa Fluor 157 633 conjugate (S21375, ThermoFisher Scientific) was then applied (1:500).

For the immunofluorescence staining of fibrosis bioassay, MPKFs plated on an 8-well chamber slide were washed before being fixed with 4% PFA-PBS. The cells were permeabilized with 0.1% Triton X-100 in PBS and then blocked with 3% BSA.

161 All images were captured using either standard or confocal microscopy (Eclipse Ti2 from 162 Nikon), with the NIS-Elements Advanced Research microscope system serving as the operating 163 system. Quantification of using ImageJ Fiji stained area was done 164 (https://imagej.net/software/fiji/downloads).

| 166 | Quantitative reverse transcription-polymerase chain reaction (qRT-PCR): The qRT-PCR                   |
|-----|---|
| 167 | analysis of human IL-1 $\beta$ , IL-6, and 18S mRNA followed established protocols. The real-time PCR |
| 168 | detection system utilized was the Thermal Cycler Dice Real Time System Lite TP700 (Takara Bio,        |
| 169 | Shiga, Japan) along with TB green Premix Ex Taq II (Takara Bio, Shiga, Japan) [38]. The total         |
| 170 | RNA was extracted from frozen kidney tubuloids stored at -80°C using Sepasol-RNAI Super G             |
| 171 | (Nacalai Tesque, Kyoto, Japan). cDNA was then synthesized from the isolated total RNA using           |
| 172 | ReverTra Ace (TOYOBO, Tokyo, Japan) [39]. The generated cDNA was then amplified through               |
| 173 | 40 PCR cycles, with denaturation at 95°C for 5 seconds and annealing/extension at 60°C for 30         |
| 174 | seconds.  |
| 175 | The nucleotide sequences of the primers utilized for qRT-PCR analysis are as follows.                 |
| 176 | human 18S.  |
| 177 | Forward:5'-GCAGAATCCACGCCAGTACAAG-3'  |
| 178 | Reverse:5'-GCTTGTTGTCCAGACCATTGGC-3'  |
| 179 | human IL-1β.  |
| 180 | Forward: 5'- CCACAGACCTTCCAGGAGAATG -3'   |
| 181 | Reverse: 5'- GTGCAGTTCAGTGATCGTACAGG -3'  |
| 182 | human IL-6.   |
| 183 | Forward 5'- AGACAGCCACTCACCTCTTCAG -3'  |
| 184 | Reverse: 5'- TTCTGCCAGTGCCTCTTTGCTG -3'   |
| 185 |   |
| 186 | Western blot analysis. The tubuloids were lysed, and the protein was purified. Protein bands were     |
| 187 | visualized using Western Blue (Promega, WI, USA). Rabbit anti-ERK2 (p44/42 MAPK) antibody             |

(9102S, Cell Signaling Technology) (1:200) was used as a loading control. Primary antibodies
were also used, such as rabbit anti-p16-INK4A polyclonal antibody (1:200) (Proteintech), mouse
anti-KIM-1 antibody (1:200) (R&D systems), rabbit anti-caspase-3 antibody (1:200) (Cell
Signaling Technology), and rabbit anti-Vimentin antibody (1:200) (Proteintech). Densitometry
was performed by using Image J Fiji (https://imagej.net/software/fiji/downloads).

193

Quantification and Statistical Analysis Figure Legends specify the number of samples assayed
in each experiment. To determine significant differences between groups, a one-way analysis of
variance was used. A p-value of less than 0.05 was considered statistically significant. All
statistical analyses were performed with GraphPad Prism by GraphPad Software Inc. (San Diego,
CA, USA).

#### 200 Results

# Primary human renal proximal tubular epithelial cells (hRPTECs) form highly polarized structure

To form tubuloids, human renal proximal tubular epithelial cells (hRPTECs) were isolated from the cortex of human kidneys, embedded in a basement membrane gel, and cultured with various growth factors (**Figure 1A**). Using precise techniques that included finely mincing the cortex portion of the human kidneys and selective culturing of epithelial cells in a serum-free medium supplemented with epidermal growth factor (EGF), primary cultured cells, primarily proximal tubular epithelial cells, were successfully established (**Figure 1B and 1C**).

209 Tubuloids were then formed over approximately a two-week protocol (Figure 1D). 210 Specifically, hRPTECs were seeded on an ultralow attachment plate (Figure 1E), followed by the 211 addition of Matrigel and media containing fetal bovine serum, EGF, fibroblast growth factor 2 212 (FGF2), and hepatocyte growth factor (HGF). Multiple tubuloids were formed in a single well, 213 with nearly uniform sizes. The epithelial cells formed tubular-like structures that encircled the 214 basement membrane gel (Figure 1F). The three-dimensional architecture was confirmed by 215 manipulating the microscope along the Z-axis direction (Figure 1G). Notably, the cells formed a 216 monolayer structure similar to tubules or renal cysts, rather than a spheroid-like structure. 217 Furthermore, tubuloids expressed differentiation markers associated with proximal tubular 218 epithelial cells, such as lotus tetragonolobus lectin (LTL) and LDL Receptor Related Protein 2 219 (LRP2/Megalin), confirming their highly differentiated and polarized structure (Figure 1H)[16]. 220

221 Cisplatin Exposure Induces Tubular Structure Collapse and Elicits Acute DNA Damage
 222 Response (DDR) in Tubuloids

223 To test the sensitivity of tubuloids against a nephrotoxicant, we exposed them to cisplatin. 224 Cisplatin causes cytotoxicity by entering proximal tubular epithelial cells primarily through 225 Organic Cation Transporter 2 (OCT2) [17], resulting in direct DNA damage (Figure 2A). 226 Consistent with previous reports highlighting the activation of DNA damage response (DDR) 227 pathways, we found significant upregulation of  $\gamma$ H2AX, a marker of DNA double-strand breaks, 228 in both *in vivo* and *in vitro* [18]. Initially, tubuloids were treated with cisplatin at three 229 concentrations of 0.2, 2.0, and 20.0 µg/mL to determine dose-dependent responses. Notably, high-230 dose cisplatin treatment collapsed the three-dimensional tubuloid architecture, (Figure 2B), 231 demonstrating the extent of DNA damage caused by cisplatin exposure (Figure 2C). Furthermore, 232 immunostaining analyses revealed a significant reduction in the expression levels of differentiation 233 markers such as LRP2 and Na+/K+-ATPase after cisplatin treatment. This downregulation 234 indicates a concomitant process of cellular dedifferentiation, possibly as an adaptive response to 235 cytotoxic insult (Figures 2D and 2E).

Additionally, there was an increase in the expression of a renal injury marker, Kidney
Injury Molecule-1 (KIM-1) [19], and an apoptosis marker, Cleaved Caspase-3 (Figure 2F, G, and
H), which was consistent with previous findings [20]. These findings further support the sensitivity
of tubuloids to cisplatin-induced injury and validate their use as a model system for studying acute
responses, including DDR.

Interestingly, we found that high concentrations of cisplatin increased the expression of Vimentin, an intermediate filament specific to mesenchymal cells (**Figure 2I and J**). This suggests that proximal tubular epithelial cells may undergo epithelial-mesenchymal transition (EMT) as part of a tissue repair mechanism [21, 22]. The activation of Vimentin following DDR has been

reported previously [23], and our study confirms this sequential response in cisplatin-treated
tubuloids, elucidating the molecular dynamics underlying cisplatin-induced nephrotoxicity.

247

#### 248 Tubuloids show cellular senescence and release inflammatory cytokines following repeated

249 **cisplatin treatment** 

250 To assess the potential for replicating chronic responses, tubuloids were subjected to prolonged 251 treatment of cisplatin. Initially, cisplatin was administered at concentrations of 0.2 and 2.0 µg/mL. 252 The media was then replaced three times to reduce residual cisplatin, and standard culture 253 conditions were applied for one day, completing one cycle. This was considered one cycle, and 254 the next day, cisplatin was given again at similar concentrations (Figure 3A). The cycle was 255 repeated five times. Although treatment with 20.0 µg/mL cisplatin caused significant disruption 256 of tubuloids and cell death (Figure 2), this concentration was excluded from the experimental 257 setup to focus on long-term chronic responses.

258 In the repeated cisplatin administration model, we observed the expression of p16, which 259 is well-established (Figure 3B, C, and D) and consistent with previous findings [24]. Additionally, 260 we confirmed an increased expression of the inflammatory cytokine IL-1 $\beta$  at a concentration of 261 2.0 µg/mL through immunofluorescence analyses (Figure 3E). Quantitative PCR analysis 262 revealed a significant upregulation in mRNA levels of both IL-1 $\beta$  and IL-6, ranging from 50 to 263 100-fold compared to controls, in the group subjected to repeated administration of 2.0  $\mu$ g/mL 264 cisplatin (P = 0.0167; IL-1 $\beta$  and P = 0.011; IL-6) (Figure 3F and G). These findings reveal that 265 repetitive DNA damage induced by cisplatin caused cellular senescence, which resulted in the 266 acquisition of an SASP.

# Secretions released from cisplatin-treated tubuloids strongly promote myofibroblast differentiation *in vitro*

270 We hypothesized that prolonged exposure of tubuloids to high concentrations of cisplatin would 271 promote myofibroblast activation, potentially contributing to tissue fibrosis via the secretion of 272 paracrine factors from tubuloids, as previously reported in vivo [25]. To test this hypothesis, we 273 used a fibrosis bioassay, as described previously [10] (Figure 4A). Initially, tubuloids were 274 divided into three groups: one receiving no cisplatin, one receiving 0.2 µg/mL cisplatin, and 275 another receiving 2.0 µg/mL cisplatin. Each group received repeated treatments. Following 276 cisplatin administrations, the medium was changed three times to remove residual cisplatin, and 277 the tubuloids were cultured for an additional 2 days in serum-free conditions to produce 278 conditioned media (CM) containing secreted paracrine factors. Subsequently, the collected CM 279 was administered to fibroblasts derived from the mouse renal cortex (Figure 4B). The activation 280 of myofibroblasts was assessed by evaluating the expression of  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA) 281 [26].

282 CM obtained from tubuloids repeatedly treated with 2.0  $\mu$ g/mL cisplatin showed the most 283 significant promotion of fibrosis (*P* = 0.0001) (**Figure 4C and D**). This concentration of cisplatin, 284 as shown in **Figure 3**, corresponds to the maximal secretion levels of IL-1 $\beta$  and IL-6 from 285 tubuloids, indicating consistency. Furthermore, direct administration of cisplatin to mouse 286 fibroblasts did not result in myofibroblast activation, decisively ruling out cisplatin as a direct 287 fibrosis inducer on fibroblasts. The fibrosis bioassay confirmed that various paracrine factors 288 secreted from tubuloids during repeated treatment of cisplatin have a fibrogenic effect on tissues. 289

#### 290 Discussion

Our findings provide compelling evidence of the negative effects of cisplatin on tubuloids, elucidating the cascade of events initiated by DNA damage induction. The dose-dependent increase in  $\gamma$ H2AX expression is a reliable indicator of DNA damage, supporting previous findings. Upon DNA damage, tubuloids exhibit a sensitive acute phase response as evidenced by increased expression of the kidney injury marker KIM-1 and the apoptosis marker Cleaved Caspase-3, which is consistent with DDR activation. There was also an increase in Vimentin expression, which indicates epithelial-mesenchymal transition (EMT).

298 The well-preserved three-dimensional structure of tubuloids collapsed upon exposure to 299 cisplatin, accompanied by a process of dedifferentiation marked by reduced expression levels of 300 Na<sup>+</sup>/K<sup>+</sup>-ATPase and LRP2/Megalin. Furthermore, repeated long-term administration of cisplatin-301 increased the expression of the cellular senescence marker, p16. Tubuloids developed a 302 senescence-associated secretory phenotype (SASP), releasing inflammatory cytokines like IL-1 $\beta$ 303 and IL-6, causing a chronic inflammatory response in surrounding tissues. These secretions from 304 tubuloids significantly increased fibrosis in the surrounding interstitial area, as confirmed by the 305 fibrosis bioassay.

306 CKD research is difficult due to the complexity of the underlying conditions. A significant 307 impediment to research into CKD is the lack of a reliable disease model. CKD is inextricably 308 linked to aging and senescence, making it particularly difficult to model in experimental settings. 309 Currently, the primary models for studying CKD are mice, which, despite their utility, live only 310 about two years. This timeframe does not adequately represent the decades-long progression of 311 chronic diseases such as CKD in humans. Furthermore, mouse models are a highly homogeneous 312 population, lacking the diversity observed in human CKD cases. Given the variability in CKD

313 progression among humans, which is influenced by factors such as gender, race, age, and 314 environmental exposures, mouse models fail to capture the complexities of human CKD 315 adequately. This discrepancy reveals a significant gap in our current understanding, emphasizing 316 the need for more robust and clinically relevant models to advance CKD research.

317 In recent years, kidney organoids derived from induced pluripotent stem cells (iPSCs) or 318 embryonic stem cells (ESCs) have emerged as promising disease models for the study of kidney 319 diseases [27-29]. However, current technologies primarily produce organoids that look like fetal 320 kidneys, making it difficult to replicate age-related features associated with CKD in older people 321 [30]. Furthermore, iPSC-derived kidney organoids require complex differentiation induction 322 procedures and skilled techniques, complicating their application. Primary cultured cells derived 323 from resected human kidneys and kept in two-dimensional conditions fail to fully replicate the 324 cellular polarity and three-dimensional structures found in living tissues. As a result, while these 325 models provide valuable insights, they have limitations that prevent them from accurately 326 representing the complexity of CKD pathogenesis and progression.

327 Conventional disease models for CKD, such as mouse models, iPSC/ESC kidney 328 organoids, and two-dimensional primary cultured cells from human kidneys, struggle to fully 329 replicate aging, senescence, and ease of production. However, the human kidney-derived tubuloids 330 developed in our study provide significant improvements over traditional pathological models for 331 CKD. Tubuloids are formed by cells obtained from patients that reflect their age and may exhibit 332 senescence, as evidenced by the control condition without cisplatin treatment (Figure 3B, C, and 333 **D**). This unique feature addresses the limitation of other models by incorporating the aging process 334 directly into the system.

The formation of tubuloids follows a remarkably simple protocol, requiring no specialized techniques. Culture is carried out in standard 24-well ultra-low attachement plates, and as shown in **Figure 1F**, multiple tubuloids develop within each well. During sample collection for western blotting, qPCR, and immunofluorescence, we harvested one sample per well as an independent condition, resulting in multiple tubuloids in each sample, effectively reducing variability across individual tubuloids.

Expanding our study to include tubuloids from multiple patients shows promise for capturing individual differences in kidney responses to various stimuli. Notably, our tubuloid production protocol allows us to derive these structures from different patients simultaneously, under uniform conditions (manuscript in preparation). These characteristics point to tubuloids' potential as a novel and useful screening tool for renal toxicity in drug discovery efforts.

346 Tubuloids have a highly differentiated three-dimensional structure[31] and mimic 347 physiological responses to nephrotoxicants[32, 33]. Previous research has shown that these well-348 differentiated tubuloids express a diverse set of channels and transporters, providing them with 349 greater physiological functionality than cells cultured in two dimensions [34]. This increased 350 physiological fidelity is likely to explain the observed sensitivity to cisplatin in our study, 351 facilitating the replication of cellular senescence and other key responses. Importantly, tubuloids 352 may capture biological reactions that are difficult to detect in conventional two-dimensional cell 353 cultures.

The primary focus of this study was cisplatin-induced nephropathy. However, our overarching goal goes beyond this single study to develop a strong pathophysiological model for CKD using human kidney-derived tubuloids. The precise mechanisms underlying CKD following cisplatin chemotherapy remain largely unknown. However, even low-dose cisplatin has been

shown to cause long-term renal pathologies similar to CKD [35]. Cisplatin-induced nephropathy is caused by the uptake of cisplatin into proximal tubular epithelial cells via OCT2, resulting in direct damage to nuclear DNA. This DNA damage initiates a cascade of DNA damage response (DDR) processes: some cells die via programmed cell death, such as apoptosis, while others activate the cell cycle in an attempt to compensate for the loss of damaged cells. When DNA damage reaches a critical threshold, it causes cell cycle arrest, particularly in the G2/M phase[2], preventing further division, a sign of cellular senescence.

Senescent cells have been shown to activate the SASP, resulting in the secretion of a variety of inflammatory and fibrotic cytokines. This cascade causes inflammation and fibrosis in the surrounding tissue while remaining resistant to cell death. This mechanism, which is driven by cellular senescence and SASP induced by DNA damage, is a significant contributor to renal fibrosis. It is an important part of the transition from AKI to CKD, as well as the broader pathophysiology of CKD, which goes beyond cisplatin-induced nephropathy.

In our tubuloid model, we found not only a highly differentiated three-dimensional structure, but also pathophysiological responses to cisplatin, such as DDR, structural collapse, dedifferentiation, cell death, epithelial-mesenchymal transition (EMT), cellular senescence, SASP activation, and fibrotic changes. Our findings suggest that tubuloids have the potential to serve as a precise disease model for cisplatin-induced nephropathy, faithfully replicating the majority of pathological mechanisms. This underscores their commitment to developing a comprehensive CKD model.

378 Moving forward, we plan to improve the sophistication of our disease models by 379 incorporating coculture systems and microfluidic technologies. Specifically, we intend to 380 coculture tubuloids with other relevant cell types, including vascular endothelial cells and

- fibroblasts. Additionally, we plan to simulate physiological urine flow using microfluidic devices
  to better mimic the *in vivo* renal microenvironment [36].
- The successful development of a highly precise disease model for cisplatin-induced nephropathy using human kidney-derived tubuloids represents a significant advance in kidney disease research. Using tubuloids as a reliable kidney disease model has great potential for improving our understanding of various kidney diseases. With their ability to faithfully replicate cellular senescence, SASP, and fibrosis, tubuloids appear to be a promising tool for modeling CKD, a condition defined by fibrosis as a final common pathological pathway.
- In conclusion, our development of tubuloids as a precise disease model for cisplatininduced nephropathy is a significant step forward in kidney disease research. Through continued refinement and innovation, we anticipate that tubuloids will play an important role in advancing our understanding of CKD and developing novel therapeutic strategies
- 393

#### **394 Disclosure Statement**

395 The authors declare that they have no conflicts of interest.

- 1. Humphreys, B.D., *Mechanisms of renal fibrosis*. Annu Rev Physiol, 2018. **80**: p. 309-326.
- 399 2. Yang, L., et al., *Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury*.
- 400 Nat Med, 2010. **16**(5): p. 535-543.
- 401 3. Sturmlechner, I., et al., *Cellular senescence in renal ageing and disease*. Nat Rev Nephrol,
- 402 2017. **13**(2): p. 77-89.
- 403 4. Docherty, M.H., et al., *Cellular senescence in the kidney*. J Am Soc Nephrol, 2019. **30**(5):
  404 p. 726-736.
- 405 5. Mylonas, K.J., et al., *Cellular senescence inhibits renal regeneration after injury in mice*,
  406 *with senolytic treatment promoting repair*. Sci Transl Med, 2021. **13**(594).
- 407 6. Takasato, M., et al., *Kidney organoids from human iPS cells contain multiple lineages and*408 *model human nephrogenesis*. Nature, 2015. **526**(7574): p. 564-568.
- 409 7. Liu, M., et al., *Studying kidney diseases using organoid models*. Front Cell Dev Biol, 2022.
  410 10: p. 845401.
- 411 8. Schutgens, F., et al., *Tubuloids derived from human adult kidney and urine for personalized*412 *disease modeling*. Nat Biotechnol, 2019. **37**(3): p. 303-313.
- 413 9. Xu, Y., et al., *Adult human kidney organoids originate from CD24+ cells and represent an*414 *advanced model for adult polycystic kidney disease*. Nat Genet, 2022. 54(11): p. 1690415 1701.
- 416 10. Mori, Y., et al., *KIM-1 mediates fatty acid uptake by renal tubular cells to promote*417 *progressive diabetic kidney disease*. Cell Metab, 2021. **33**(5): p. 1042-1061.e7.
- 418 11. Latcha, S., et al., *Long-term renal outcomes after cisplatin treatment*. Clin J Am Soc
  419 Nephrol, 2016. **11**(7): p. 1173-1179.

| 420 | 12. | McSweeney, K.R., et al., Mechanisms of cisplatin-induced acute kidney injury:                 |
|-----|-----|---|
| 421 |     | pathological mechanisms, pharmacological interventions, and genetic mitigations.              |
| 422 |     | Cancers (Basel), 2021. 13(7).   |
| 423 | 13. | Miller, R.P., et al., Mechanisms of cisplatin nephrotoxicity. Toxins (Basel), 2010. 2(11): p. |
| 424 |     | 2490-2518.  |
| 425 | 14. | Sato, Y., M. Takahashi, and M. Yanagita, Pathophysiology of AKI to CKD progression.           |
| 426 |     | Semin Nephrol, 2020. 40(2): p. 206-215.   |
| 427 | 15. | Ferenbach, D.A. and J.V. Bonventre, Mechanisms of maladaptive repair after AKI leading        |
| 428 |     | to accelerated kidney ageing and CKD. Nat Rev Nephrol, 2015. 11(5): p. 264-276.               |
| 429 | 16. | Nielsen, R., E.I. Christensen, and H. Birn, Megalin and cubilin in proximal tubule protein    |
| 430 |     | reabsorption: from experimental models to human disease. Kidney Int, 2016. 89(1): p. 58-      |
| 431 |     | 67.   |
| 432 | 17. | Mody, H., et al., Pharmacodynamic modeling to evaluate the impact of cimetidine, an           |
| 433 |     | OCT2 inhibitor, on the anticancer effects of cisplatin. Cells, 2022. 12(1).                   |
| 434 | 18. | Kuo, L.J. and L.X. Yang, Gamma-H2AX - a novel biomarker for DNA double-strand                 |
| 435 |     | breaks. In Vivo, 2008. 22(3): p. 305-309.   |
| 436 | 19. | Han, W.K., et al., Kidney injury Molecule-1 (KIM-1): a novel biomarker for human renal        |
| 437 |     | proximal tubule injury. Kidney Int, 2002. 62(1): p. 237-244.                                  |
| 438 | 20. | Tang, C., et al., Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat    |
| 439 |     | Rev Nephrol, 2023. <b>19</b> (1): p. 53-72.   |
| 440 | 21. | Lovisa, S., et al., Epithelial-to-mesenchymal transition induces cell cycle arrest and        |
|     |     |   |

441 *parenchymal damage in renal fibrosis*. Nat Med, 2015. **21**(9): p. 998-1009.

- Grande, M.T., et al., *Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease*. Nat Med, 2015.
- 444 **21**(9): p. 989-997.
- 445 23. Patteson, A.E., et al., *Vimentin protects cells against nuclear rupture and DNA damage*
- 446 *during migration*. J Cell Biol, 2019. **218**(12): p. 4079-4092.
- 447 24. Li, S., et al., *Tubular cell senescence promotes maladaptive kidney repair and chronic*448 *kidney disease after cisplatin nephrotoxicity*. JCI Insight, 2023. 8(8).
- Liu, B.C., et al., *Renal tubule injury: a driving force toward chronic kidney disease*. Kidney
  Int, 2018. **93**(3): p. 568-579.
- 451 26. LeBleu, V.S., et al., Origin and function of myofibroblasts in kidney fibrosis. Nat Med,
  452 2013. 19(8): p. 1047-1053.
- 453 27. Gupta, N., et al., *Modeling injury and repair in kidney organoids reveals that homologous*
- 454 recombination governs tubular intrinsic repair. Sci Transl Med, 2022. 14(634): p.
  455 eabj4772.
- 456 28. Hiratsuka, K., et al., Organoid-on-a-chip model of human ARPKD reveals mechanosensing
  457 pathomechanisms for drug discovery. Sci Adv, 2022. 8(38): p. eabq0866.
- Tabibzadeh, N., et al., *Navigating the kidney organoid: insights into assessment and enhancement of nephron function*. Am J Physiol Renal Physiol, 2023. 325(6): p. F695F706.
- 461 30. Yousef Yengej, F.A., et al., *Kidney organoids and tubuloids*. Cells, 2020. 9(6).
- 462 31. Yousef Yengej, F.A., et al., *Tubuloid differentiation to model the human distal nephron*463 *and collecting duct in health and disease*. Cell Rep, 2024. 43(1): p. 113614.

| 464 | 32.    | Wiraja, C., et al., Nephrotoxicity assessment with human kidney tubuloids using spherical    |
|-----|--------|--|
| 465 |        | nucleic acid-based mRNA nanoflares. Nano Lett, 2021. 21(13): p. 5850-5858.                   |
| 466 | 33.    | Vidal Yucha, S.E. et al., 3D, human renal proximal tubule (RPTEC-TERT1) organoids            |
| 467 |        | 'tubuloids' for translatable evaluation of nephrotoxins in high-throughput. PLOS ONE,        |
| 468 |        | 2022. 17(11): e0277937.  |
| 469 | 34.    | Yousef Yengej, F.A., et al., Tubuloid differentiation to model the human distal nephron      |
| 470 |        | and collecting duct in health and disease. Cell Rep, 2024. 43(1): p. 113614.                 |
| 471 | 35.    | Fu, Y., et al., Chronic effects of repeated low-dose cisplatin treatment in mouse kidneys    |
| 472 |        | and renal tubular cells. Am J Physiol Renal Physiol, 2019. 317(6): p. F1582-F1592.           |
| 473 | 36.    | Gijzen, L., et al., Culture and analysis of kidney tubuloids and perfused tubuloid cells-on- |
| 474 |        | <i>a-chip</i> . Nat Protoc, 2021. <b>16</b> (4): p. 2023-2050.                               |
| 475 | 37.    | Ichimura, T., et al., Kidney injury molecule-1 is a phosphatidylserine receptor that confers |
| 476 |        | a phagocytic phenotype on epithelial cells. J Clin Invest, 2008. 118(5): p. 1657-1668.       |
| 477 | 38.    | Cong, W., et al., Implications of the Wnt5a/CaMKII pathway in retinoic acid-induced          |
| 478 |        | myogenic tongue abnormalities of developing mice. Sci Rep, 2014. 4: p. 6082.                 |
| 479 | 39.    | Takai, J., et al., Heterozygous mutant mice exhibit reduced inflammatory responses and       |
| 480 |        | impaired bacterial clearance. iScience, 2021. 24(8): p. 102836.                              |
| 481 |        |  |
| 482 | Ackn   | owledgment   |
| 483 | We an  | re deeply grateful to the generous study participants who agreed to donate segments of their |
| 484 | resect | ted kidneys for this research.   |

#### 486 Funding

| 487   | This work was supported by various sources, including the Leading Initiative for Excellent Young   |
|---|--|
| 488   | Researchers from Ministry of Education, Culture, Sports, Science, and Technology (to Y.M.),  |
| 489   | Grant-in-Aid for Research Activity Start-up from Japan Society for the Promotion of Science  |
| 490   | (22K20881) (to Y.M.), Innovation Idea Contest from Tokyo Medical and Dental University   |
| 491   | (TMDU) (in 2022 to Y.M. and in 2023 to Y.N.), Next Generation Researcher Training Unit from  |
| 492   | TMDU (to Y.M.) and Priority Research Areas Grant from TMDU (to Y.M.), Research Grant from  |
| 493   | Uehara Memorial Foundation (to Y.M.), Research Grant (Lifestyle-related diseases) from MSD   |
| 494   | Life Science Foundation (to Y.M.), Medical Research Grant from Takeda Science Foundation (to   |
| 495   | Y.M.), and Academic Support from Bayer Yakuhin, Ltd. (to Y.M.).  |
| 496   |  |
|   |  |
| 497   | Data availability statements   |
| 497<br>498  | Data availability statements<br>The data that support the findings of this study are available from the corresponding author upon  |
| 497<br>498<br>499   | Data availability statements The data that support the findings of this study are available from the corresponding author upon reasonable request. Requests for resources and reagents should be directed to the Lead Contact,   |
| 497<br>498<br>499<br>500  | Data availability statements<br>The data that support the findings of this study are available from the corresponding author upon<br>reasonable request. Requests for resources and reagents should be directed to the Lead Contact,<br>Yutaro Mori (y-mori.kid@tmd.ac.jp).  |
| 497<br>498<br>499<br>500<br>501   | Data availability statements<br>The data that support the findings of this study are available from the corresponding author upon<br>reasonable request. Requests for resources and reagents should be directed to the Lead Contact,<br>Yutaro Mori (y-mori.kid@tmd.ac.jp).  |
| <ol> <li>497</li> <li>498</li> <li>499</li> <li>500</li> <li>501</li> <li>502</li> </ol>  | Data availability statements         The data that support the findings of this study are available from the corresponding author upon         reasonable request. Requests for resources and reagents should be directed to the Lead Contact,         Yutaro Mori (y-mori.kid@tmd.ac.jp).   |
| <ul> <li>497</li> <li>498</li> <li>499</li> <li>500</li> <li>501</li> <li>502</li> <li>503</li> </ul>                           | Data availability statements         The data that support the findings of this study are available from the corresponding author upon         reasonable request. Requests for resources and reagents should be directed to the Lead Contact,         Yutaro Mori (y-mori.kid@tmd.ac.jp).         Author contributions         Y.N. and Y.M.: performed the experiments, collected and analyzed data, and prepared the  |
| <ul> <li>497</li> <li>498</li> <li>499</li> <li>500</li> <li>501</li> <li>502</li> <li>503</li> <li>504</li> </ul>              | Data availability statements         The data that support the findings of this study are available from the corresponding author upon         reasonable request. Requests for resources and reagents should be directed to the Lead Contact,         Yutaro Mori (y-mori.kid@tmd.ac.jp).         Author contributions         Y.N. and Y.M.: performed the experiments, collected and analyzed data, and prepared the         manuscript.  |
| <ul> <li>497</li> <li>498</li> <li>499</li> <li>500</li> <li>501</li> <li>502</li> <li>503</li> <li>504</li> <li>505</li> </ul> | Data availability statements         The data that support the findings of this study are available from the corresponding author upon         reasonable request. Requests for resources and reagents should be directed to the Lead Contact,         Yutaro Mori (y-mori.kid@tmd.ac.jp).         Author contributions         Y.N. and Y.M.: performed the experiments, collected and analyzed data, and prepared the         manuscript.         Y.M. and M.M.: established the hRPTECs and S.M. helped with the procedure. |

507 Y.W., S.Y., and Y.F.: resected the patients' kidneys as standard treatment for malignant diseases.

508 Y.M.: developed experimental strategy, supervised the project, and finalized the manuscript.

509 All authors discussed the results and implications and provided comments on the manuscript.

510

#### 512 Figure Legends

#### 513 Figure 1. Formation of highly polarized tubuloid structures from primary human renal

#### 514 proximal tubular epithelial cells (hRPTECs).

- 515 (A) Schematic overview of the establishment of tubuloids from hRPTECs isolated from adult
- 516 human kidney.
- 517 (B) Image of the human resected kidney utilized during the establishment of hRPTECs.
- 518 (C) Representative image showing hRPTECs. Scale bars: 50 µm.
- 519 (D) Two-week protocol for generating tubuloids from 2D-cultured hRPTECs.
- 520 (E) Representative image demonstrating the seeding of hRPTECs on an ultralow attachment plate.
- 521 Scale bars:  $25 \mu m$ .
- 522 (F) Representative images of tubuloids at different magnifications ( $\times 10$ ,  $\times 40$ ). Scale bars: 100  $\mu$ m,
- 523 25 μm.
- 524 (G) Representative image of tubuloids at ×40 magnification, showing multiple layers along the Z
  525 axis. Scale bars: 25 μm.
- 526 (H) Immunostaining of makers for renal proximal tubular epithelial cells (LRP2/Megalin and
  527 LTL). Scale bars: 25 μm.
- 528
- 529

# Figure 2. Effects of cisplatin treatment on tubuloid structure, DNA damage response, differentiation loss, cell death, and epithelial-mesenchymal transition.

- 532 (A) Schematic representation of the pathway by which cisplatin induces DNA damage in proximal
- 533 tubular epithelial cells.
- 534 (**B**) Representative images of tubuloids exposed to cisplatin (0.2, 2.0, 20.0 μg/mL) or control.

- 535 (C) Immunostaining of the DNA damage marker,  $\gamma$ H2AX, in tubuloids exposed to cisplatin (0.2,
- 536 2.0, 20.0 μg/mL) or control. Scale bars: 100 μm. (**D**) Immunostaining of a differentiation marker
- 537 for epithelial cells, LRP2/Megalin in tubuloids exposed to cisplatin (20.0 µg/mL) or control. Scale
- 538 bars: 25 μm.
- 539 (E) Immunostaining of a differentiation marker for epithelial cells, Na<sup>+</sup>/K<sup>+</sup>-ATPase in tubuloids
- 540 exposed to cisplatin (20.0  $\mu$ g/mL) or control. Scale bars: 25  $\mu$ m.
- 541 (F) Immunostaining of an epithelial injury marker, Kidney Injury Molecule-1 (KIM-1) in tubuloids
- 542 exposed to cisplatin (20.0  $\mu$ g/mL) or control. Scale bars: 25  $\mu$ m.
- 543 (G) Western blotting analysis of KIM-1 in tubuloids exposed to cisplatin (0.2, 2.0 µg/mL) or

544 control.

- 545 (H) Immunostaining of an apoptosis marker, Cleaved Caspase-3, in tubuloids exposed to cisplatin
- 546 (20.0  $\mu$ g/mL) or control. Scale bars: 25  $\mu$ m.
- 547 (I) Immunostaining of intermediate filament, Vimentin, in tubuloids exposed to cisplatin (20.0
  548 μg/mL) or control. Scale bars: 100 μm.
- 549 (**J**) Western blotting analysis of Vimentin in tubuloids exposed to cisplatin (0.2, 2.0  $\mu$ g/mL) or 550 control.
- 551

#### 552 Figure 3. Tubuloids exhibit cellular senescence and release inflammatory cytokines following

- 553 repeated cisplatin treatment.
- 554 (A) Experimental design for repeated cisplatin injury.
- (B) Western blotting analysis of p16 in tubuloids exposed to cisplatin (0.2, 2.0 µg/mL) repeatedly
  or control.
- 557 (C) Quantification of relative protein levels of p16 / ERK1/2. \*P = 0.0233 (n = 4).

- 558 (**D**) Immunostaining of p16 in tubuloids exposed to cisplatin ( $2.0 \mu g/mL$ ) repeatedly or control.
- 559 Scale bars: 100 µm.
- 560 (E) Immunostaining of an inflammatory cytokine, IL-1 $\beta$ , in tubuloids exposed to cisplatin (2.0
- 561  $\mu$ g/mL) repeatedly or control. Scale bars: 100  $\mu$ m.
- 562 (F) Quantitative PCR of IL-1 $\beta$  and IL-6 in tubuloids exposed to cisplatin (0.2, 2.0  $\mu$ g/mL)
- 563 repeatedly or control. Statistical analysis was applied to the delta-delta Ct value, not fold increase.

564 
$$*P = 0.0167 (n = 3), **P = 0.0011 (n = 3).$$

565

Figure 4. Secretion released from cisplatin-treated tubuloids strongly promotes fibrosis in *vitro*.

- 568 (A) Experimental design for fibrosis bioassay.
- 569 (**B**) A representative image of Mouse Primary Kidney Fibroblasts (MPKFs). Scale bar: 25 μm.
- 570 (C) Representative images of fibrosis bioassay on MPKFs cultured with Conditioned Media (CM)
- 571 harvested from tubuloids exposed to cisplatin (0.2, 2.0 µg/mL) or control, or directly with
- 572 cisplatin-containing media. Scale bars: 100 μm.
- 573 (D) Quantification of the  $\alpha$ SMA-positive area in MPKFs cultured with CM or directly with
- 574 cisplatin-containing media measured by Image J. \*\*P = 0.0021, \*\*\*P = 0.0001, \*\*\*\*P < 0.0001.
- 575 (n = 8-10 each condition)
- 576



### **Graphical Abstract**



Move in Z-axis direction

## Figure 1



### Figure 2



### Figure 3



## Figure 4